Literature DB >> 17410461

Acid-suppressive effects of various regimens of omeprazole in Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers: which regimen has the strongest effect?

Tomohiko Shimatani1, Tomoko Kuroiwa, Mutsuko Moriwaki, Jing Xu, Susumu Tazuma, Masaki Inoue.   

Abstract

To achieve more potent and long-lasting acid suppression, omeprazole was administered for 7 days in 5 regimens: 10, 20, and 40 mg once daily (od), and 10 and 20 mg twice daily (bid), in 7 healthy Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers, and intragastric pH was continuously measured. The median intragastric pH and percent time pH > 4.0 for 24 hours increased dose dependently with 10, 20, and 40 mg od. Ten and 20 mg bid wre comparable to 20 and 40 mg od, respectively. Concerning percent time pH > 4.0 in the nighttime (20:00-8:00 hours), 20 mg bid was significantly superior to 40 mg od (P < .05). In 4 of the 5 regimens, all 7 subjects had nocturnal acid breakthrough, whereas with 20 mg bid it occurred in only 3. We concluded that, considering nighttime acid suppression, omeprazole 20 mg bid had the strongest effect.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17410461     DOI: 10.1007/s10620-006-9643-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  36 in total

Review 1.  Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.

Authors:  C A Stedman; M L Barclay
Journal:  Aliment Pharmacol Ther       Date:  2000-08       Impact factor: 8.171

2.  Intravenous pentagastrin can induce the illusion of 'tolerance' to a single dose of an H2-blocker in man.

Authors:  C U Nwokolo; A Sawyerr; J T Smith; R E Pounder
Journal:  Aliment Pharmacol Ther       Date:  1990       Impact factor: 8.171

3.  Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease.

Authors:  J Naesdal; G Bodemar; A Walan
Journal:  Scand J Gastroenterol       Date:  1984-10       Impact factor: 2.423

4.  Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations.

Authors:  C M Bate; P W Keeling; C O'Morain; S P Wilkinson; D N Foster; R A Mountford; J M Temperley; R F Harvey; D G Thompson; M Davis
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

5.  CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.

Authors:  T Furuta; K Ohashi; K Kosuge; X J Zhao; M Takashima; M Kimura; M Nishimoto; H Hanai; E Kaneko; T Ishizaki
Journal:  Clin Pharmacol Ther       Date:  1999-05       Impact factor: 6.875

6.  Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis.

Authors:  K Adachi; H Fujishiro; T Katsube; M Yuki; M Ono; A Kawamura; M A Rumi; M Watanabe; Y Kinoshita
Journal:  J Gastroenterol Hepatol       Date:  2001-11       Impact factor: 4.029

7.  Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors.

Authors:  P L Peghini; P O Katz; N A Bracy; D O Castell
Journal:  Am J Gastroenterol       Date:  1998-05       Impact factor: 10.864

8.  Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.

Authors:  J Dent; N D Yeomans; M Mackinnon; W Reed; F M Narielvala; D J Hetzel; E Solcia; D J Shearman
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

9.  Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine.

Authors:  G Bianchi Porro; F Pace; A Peracchia; L Bonavina; S Vigneri; A Scialabba; M Franceschi
Journal:  J Clin Gastroenterol       Date:  1992-10       Impact factor: 3.062

10.  A comparison of five maintenance therapies for reflux esophagitis.

Authors:  S Vigneri; R Termini; G Leandro; S Badalamenti; M Pantalena; V Savarino; F Di Mario; G Battaglia; G S Mela; A Pilotto
Journal:  N Engl J Med       Date:  1995-10-26       Impact factor: 91.245

View more
  1 in total

Review 1.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.